⌕
Celldex Therapeutics · CLDX · Nasdaq
Tenet 44 · Weak
Compare
$28.04−1.92%At closeTenet 44 · Weak
$28.04−0.55 (−1.92%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Celldex Therapeutics (CLDX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CLDX's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 10, 2026 · 01:13 ET
Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results

Celldex Therapeutics NASDAQ: CLDX plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week data from its Phase 3 studies in chronic spontaneous urticaria, executives said at Guggenhei…

CLDX −1.9% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd Annual Healthcare Innovat…

CLDX −1.9% todayRead at source ↗
● PRNewsWireOct 12, 2026 · 09:10 ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine w…

CLDX −1.9% todayRead at source ↗
● Defense WorldOct 5, 2026 · 03:00 ET
Head-To-Head Analysis: Senti Biosciences (NASDAQ:SNTI) and Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Senti Biosciences (NASDAQ: SNTI - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the s…

CLDX −1.9% todayRead at source ↗
● Defense WorldSep 24, 2026 · 05:21 ET
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Down – What’s Next?

Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $37.89, but opened at $36.60. Celldex Therapeutics shares last traded at $35…

CLDX −1.9% todayRead at source ↗
● Defense WorldSep 23, 2026 · 05:09 ET
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Celldex Therapeutics (NASDAQ: CLDX) reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 …

CLDX −1.9% todayRead at source ↗
● Seeking AlphaSep 22, 2026 · 15:19 ET
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript…

CLDX −1.9% todayRead at source ↗
● BenzingaSep 22, 2026 · 12:25 ET
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (…

CLDX −1.9% todayRead at source ↗
● Zacks Investment ResearchSep 22, 2026 · 11:56 ET
4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.…

CLDX −1.9% todayRead at source ↗
● ReutersSep 22, 2026 · 07:40 ET
Celldex's skin disease drug meets goals in two late-stage trials

Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary ​goals of two late-stage trials.…

CLDX −1.9% todayRead at source ↗
● GlobeNewsWireSep 22, 2026 · 06:58 ETCOMPANY'S OWN WORDS
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 wee…

CLDX −1.9% todayRead at source ↗
● Defense WorldSep 21, 2026 · 02:29 ET
Head-To-Head Survey: Celldex Therapeutics (NASDAQ:CLDX) & Bicycle Therapeutics (NASDAQ:BCYC)

Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses base…

CLDX −1.9% todayRead at source ↗
● Defense WorldSep 18, 2026 · 03:16 ET
Engineers Gate Manager LP Takes $1.26 Million Position in Celldex Therapeutics, Inc. $CLDX

Engineers Gate Manager LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ: CLDX) in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquire…

CLDX −1.9% todayRead at source ↗
● Defense WorldSep 17, 2026 · 03:32 ET
Head-To-Head Comparison: Precigen (NASDAQ:PGEN) and Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Precigen (NASDAQ: PGEN - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the…

CLDX −1.9% todayRead at source ↗
● Defense WorldSep 16, 2026 · 01:29 ET
Seres Therapeutics (NASDAQ:MCRB) and Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review

Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Seres Therapeutics (NASDAQ: MCRB - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on t…

CLDX −1.9% todayRead at source ↗
● GlobeNewsWireSep 8, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:0…

CLDX −1.9% todayRead at source ↗
● PRNewsWireAug 24, 2026 · 08:45 ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine w…

CLDX −1.9% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA33−0.4%
DLB4−3.8%
WDAY4−5.8%

Article counts from the last market-wide feed page, across every symbol we track and not just CLDX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.